RenovoDerm receives FDA approval for Phoenix Wound Matrix

Phoenix Wound Matrix (1).png
IMG_5385+(1).jpeg

Today, RenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix, which is a wound care device that accelerates the body’s healing response, facilitates tissue growth and regeneration, reduces scar formation and enhances overall cosmesis.

The Phoenix Wound Matrix is a fully resorbable synthetic graft that closely mimics the extracellular matrix (ECM) found naturally in the body. This product will be used for the treatment of acute, chronic, and burn wounds, which continues to be a concern for both doctors and patients.